Exhibit 10.10.1

 

First Amendment to securities purchase agreement

 

This First Amendment to Securities Purchase Agreement (the “Amendment”), dated as of November 3, 2026, is made by and between BirchBioMed Inc., a British Columbia corporation (the “Company”), and Streeterville Capital, LLC, a Utah limited liability company (the “Investor”). The parties hereto are referred to collectively as the “Parties” and individually as a “Party”.

 

A. The Parties entered into that certain Securities Purchase Agreement dated October 1, 2026 (the “Purchase Agreement”).

 

B. The Parties desire to amend the Purchase Agreement to amend the timing of the sale of the Warrant by the Company and purchase of the Warrant by Investor.

 

NOW, THEREFORE, in consideration of the terms and conditions set forth herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

 

1. Definitions. Capitalized terms used and not otherwise defined herein have the meaning ascribed to such terms in the Purchase Agreement.

 

2. Amendment to Purchase Agreement.

 

2.1. Section 1.1 of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

“1.1 Closing.

 

(a) Initial Pre-Paid Purchase. Subject to the satisfaction (or written waiver) of the conditions set forth in Section 8.1 and Section 9.1 below, the date of the issuance and sale of Pre-Paid Purchase #1 in the original principal amount of $5,425,000.00 (the “Initial Pre-Paid Purchase”), and the Commitment Shares pursuant to this Agreement shall be the date that the Common Shares are listed for trading on Nasdaq (the “Initial Listing Date”), or another mutually agreed upon date (the “Initial Pre-Paid Closing Date”). On the Initial Pre-Paid Closing Date, Investor shall pay to Company the Initial Purchase Price (as defined below) via wire transfer of immediately available funds against delivery of the Initial Pre-Paid Purchase and the Commitment Shares. The Commitment Shares will be fully earned and non-refundable on the Initial Pre-Paid Closing Date.

 

(b) Warrant. Subject to the satisfaction (or written waiver) of the conditions set forth in Section 8.2 and Section 9.2 below, the date of the issuance and sale of the Warrant pursuant to this Agreement shall be November 3, 2026, or another mutually agreed upon date (the “Warrant Closing Date”, and together with the Initial Pre-Paid Closing Date, the “Closing Date”). On the Warrant Closing Date, Investor shall pay to Company the Warrant Price (as defined below) via wire transfer of immediately available funds against delivery of the Warrant.”

 

2.2. Section 1.2 of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

“1.2 Purchase Price. The Initial Pre-Paid Purchase carries an original issue discount of $400,000.00 (“OID”). In addition, Company agrees to pay $25,000.00 to Investor to cover Investor’s legal fees, accounting costs, due diligence, monitoring and other transaction costs incurred in connection with the purchase and sale of all Pre-Paid Purchases (the “Transaction Expense Amount”). The OID and Transaction Expense Amount will be included in the initial principal balance of the Initial Pre-Paid Purchase. The “Initial Purchase Price”, therefore, shall be $5,000,000.00, computed as follows: $5,425,000.00 initial principal balance, less the OID, less the Transaction Expense Amount. In addition to the Initial Purchase Price, Investor will also pay $5,333.00 to Company for the Warrant (the “Warrant Price”).”

 

1
 

 

2.3. Section 8 of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

“8. Conditions to Company’s Obligation to Sell.

 

8.1. Initial Pre-Paid Purchase. The obligation of Company hereunder to issue and sell the Initial Pre-Paid Purchase to Investor at the Initial Pre-Paid Closing is subject to the satisfaction, on or before the Initial Pre-Paid Closing Date, of each of the following conditions:

 

(a) Investor shall have executed and delivered all applicable Transaction Documents to Company.

 

(b) Investor shall have delivered the Initial Pre-Paid Purchase Price to Company.

 

(c) The Initial Listing Date shall have occurred.

 

8.2. Warrant. The obligation of Company hereunder to issue and sell the Warrant to Investor at the Warrant Closing Date is subject to the satisfaction, on or before the Warrant Closing Date, of each of the following conditions:

 

(a) Investor shall have executed and delivered all applicable Transaction Documents to Company.

 

(b) Investor shall have delivered the Warrant Price to Company.”

 

2.4. Section 9 of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

“9. Conditions to Investor’s Obligation to Purchase.

 

9.1. Initial Pre-Paid Purchase. The obligation of Investor hereunder to purchase the Initial Pre-Paid Purchase at the Initial Pre-Paid Closing Date is subject to the satisfaction, on or before the Initial Pre-Paid Closing Date, of each of the following conditions, provided that these conditions are for Investor’s sole benefit and may be waived by Investor at any time in its sole discretion:

 

(a) Company shall have executed this Agreement and the Initial Pre-Paid Purchase and delivered the same to Investor.

 

(b) Company’s transfer agent (the “Transfer Agent”) shall have executed an Irrevocable Transfer Agent Instruction Letter substantially in the form attached hereto as Exhibit C.

 

2
 

 

(c) Company shall have delivered to Investor a fully executed Officer’s Certificate substantially in the form attached hereto as Exhibit D evidencing Company’s approval of the Transaction Documents.

 

(d) Company shall have delivered to Investor a fully executed Share Issuance Resolution substantially in the form attached hereto as Exhibit E.

 

(e) Company shall have issued the Commitment Shares.

 

(f) The Initial Listing Date shall have occurred.

 

(g) The First Registration Statement, as amended, shall be effective and include the resale of the Commitment Shares and the Warrant Shares.

 

(h) Company shall have received the Approval.

 

(i) Lock-Up Agreements executed in a form satisfactory to Investor executed by Company’s officers and directors pursuant to which they agree to be locked up from selling Common Shares for a period of ninety (90) days following the effective date of the effectiveness of the Second Registration Statement.

 

(j) Company shall have delivered to Investor fully executed copies of all other Transaction Documents required to be executed by Company herein or therein.

 

9.2. Warrant. The obligation of Investor hereunder to purchase the Warrant at the Warrant Closing Date is subject to the satisfaction, on or before the Warrant Closing Date, of each of the following conditions, provided that these conditions are for Investor’s sole benefit and may be waived by Investor at any time in its sole discretion:

 

(a) Company shall have executed this Agreement and the Warrant and delivered the same to Investor.

 

(b) Company shall have delivered to Investor a fully executed Officer’s Certificate evidencing Company’s approval of the Warrant.

 

(c) Company shall have delivered to Investor a fully executed Share Issuance Resolution related to the Warrant Shares.”

 

2.5. Section 12 of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

“12. Reinvestment Right. At any time during the period beginning on the Initial Pre-Paid Closing Date and ending on the later of: (i) the date that is one (1) year after the Initial Pre-Paid Closing Date, and (ii) the date that the Pre-Paid Purchase Outstanding Balance reaches zero, Investor will have the right, but not the obligation, to purchase up to an additional $1,500,000.00 in Pre-Paid Purchases in one or more tranches. Purchases of additional Pre-Paid Purchases pursuant to this Section 12 will be reduced from the Commitment Amount.”

 

3
 

 

2.6. Section 13.4 of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

“13.4. “Commitment Period” means the period beginning on the Initial Pre-Paid Closing Date and ending on the earlier of: (i) the date that is eighteen (18) months from the Initial Pre-Paid Closing Date, (ii) the date Company has sold $15,000,000.00 in Pre-Paid Purchases hereunder; and (iii) termination of this Agreement. Notwithstanding the foregoing, in the event that a definitive agreement that contemplates a Change of Control is entered into after the Initial Pre-Paid Closing Date, the Commitment Period for any Pre-Paid Purchases shall automatically terminate immediately prior to the consummation of such Change of Control. Company may waive this condition subsequent, at its sole discretion. For the avoidance of doubt, the termination of the Commitment Period will not affect Company’s obligations with respect to Pre-Paid Purchases issued prior to the termination of the Commitment Period.”

 

2.7. Exhibit B of the Purchase Agreement is hereby amended and restated in its entirety in the form attached hereto as Exhibit B.

 

3. Reference to and Effect on the Purchase Agreement. Except as specifically modified or amended by the terms of this Amendment, the Purchase Agreement and all provisions contained therein are, and shall continue, in full force and effect and are hereby ratified and confirmed. All references in the Purchase Agreement to itself shall be deemed references to the Purchase Agreement as amended hereby.

 

4. Counterparts. This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be signed electronically (including any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes

 

5. Arbitration of Claims. The parties shall submit all Claims arising under this Amendment to binding arbitration pursuant to the provisions set forth in Section 14.1 of the Agreement, which is incorporated herein by reference.

 

6. Governing Law; Venue. This Amendment shall be construed and enforced in accordance with the governing law and venue provisions set forth in Section 14.2 of the Agreement, which is incorporated herein by reference.

 

7. Successors and Assigns. This Amendment or any of the severable rights and obligations inuring to the benefit of or to be performed by Investor hereunder may be assigned by Investor to a third party, including its affiliates, in whole or in part, without the need to obtain Company’s consent thereto. Company may not assign its rights or obligations under this Amendment or delegate its duties hereunder, whether directly or indirectly, without the prior written consent of Investor, and any such attempted assignment or delegation shall be null and void.

 

8. Headings. The headings of this Amendment are for convenience of reference only and shall not form part of, or affect the interpretation of, this Amendment.

 

[Remainder of page intentionally left blank; signature page follows]

 

4
 

 

IN WITNESS WHEREOF, the undersigned Investor and Company have caused this Amendment to be duly executed as of the date first above written.

 

  INVESTOR:
   
  Streeterville Capital, LLC
     
  By: /s/ John Fife
    John Fife, President
     
  COMPANY:
   
  BirchBioMed Inc.
     
  By: /s/ Mark S. Miller
    Mark S. Miller, Chief Executive Officer

 

[Signature Page to First Amendment to Securities Purchase Agreement]

 

5
 

 

EXHIBIT A

 

[Intentionally omitted]

 

6
 

 

EXHIBIT B

 

WARRANT TO PURCHASE COMMON SHARES

 

1. Issuance. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by BirchBioMed Inc., a British Columbia corporation (“Company”); Streeterville Capital, LLC, a Utah limited liability company (“Investor”), is hereby granted the right to purchase a number of fully paid and non-assessable Common Shares equal to $8,000,000.00 divided by the Nasdaq Valuation Price (the “Warrant Shares”), pursuant to the terms and conditions of this Warrant to purchase Common Shares (this “Warrant”). Certain capitalized terms used herein are defined in Attachment 1 attached hereto and incorporated herein by this reference. Moreover, to the extent any defined terms herein are defined in any other Transaction Document (as so noted herein), such defined term shall remain applicable in this Warrant even if the other Transaction Document has been released, satisfied, or is otherwise cancelled. All references to $ or dollars herein are to United States dollars.

 

This Warrant is being issued pursuant to the terms of that certain Securities Purchase Agreement dated October 1, 2026, as amended by the First Amendment to Securities Purchase Agreement dated November 3, 2026, to which Company and Investor are parties (as the same may be further amended from time to time, the “Purchase Agreement”). This Warrant was issued to Investor on November 3, 2026 (the “Issue Date”).

 

2. Exercise of Warrant.

 

2.1. General.

 

(a) This Warrant is exercisable in whole or in part at any time and from time to time commencing on the Initial Pre-Paid Closing Date and ending on the Expiration Date. Such exercise shall be effectuated by Investor submitting to Company via email a completed and signed Notice of Exercise substantially in the form attached to this Warrant as Exhibit A (the “Notice of Exercise”). The date a Notice of Exercise is received by Company shall be the exercise date. The Notice of Exercise shall be executed by Investor and shall indicate the number of Warrant Shares to be issued pursuant to such exercise.

 

(b) The Exercise Price per Common Share for the Warrant Shares shall be payable, at the election of Investor, in cash or by certified or official bank check or by wire transfer in accordance with instructions provided by Company at the request of Investor.

 

(c) Upon the payment to Company of the Exercise Price for the Warrant Shares, Company shall promptly, but in no case later than the date that is two (2) Trading Days following the date the Exercise Price is paid to Company, deliver or cause Company’s Transfer Agent to deliver the applicable Warrant Shares electronically via the DWAC system to the account designated by Investor on the Notice of Exercise (or issued in book entry form if such shares would not be eligible for electronic transfer).

 

(d) If Warrant Shares are delivered later than as required under subsection (c) immediately above, Company agrees to pay, in addition to all other remedies available to Investor in the Transaction Documents, a late charge equal to the greater of (i) $500.00 and (ii) 2% of the product of (1) the number of Common Shares not issued to Investor on a timely basis and to which Investor is entitled multiplied by (2) the VWAP of the Common Shares on the Trading Day immediately preceding the last possible date which Company could have issued such Common Shares to Investor without violating this Warrant, rounded to the nearest multiple of $100.00 (such resulting amount, the “Warrant Share Value”) (but in any event the cumulative amount of such late fees for each exercise shall not exceed 200% of the Warrant Share Value), per Trading Day until such Warrant Shares are delivered (the “Late Fees”). Company acknowledges and agrees that the failure to timely deliver Warrant Shares hereunder is a material breach of this Warrant and that the Late Fees are properly charged as liquidated damages to compensate Investor for such breach.

 

7
 

 

(e) At any time following the date that is six (6) months from the Listing Date, Company may terminate this Warrant by providing ten (10) days’ prior written notice of termination to Investor. For the avoidance of doubt, during such ten (10) day notice period, Investor may exercise all or any portion of this Warrant.

 

(f) The Investor acknowledges and agrees that the right to exercise this Warrant is expressly contingent upon the occurrence of the Initial Pre-Paid Purchase pursuant to the Purchase Agreement. If such condition is not fully satisfied and the Initial Pre-Paid Purchase Closing Date completed (or waived in writing by the Company) on or before the 180th day following the Issue Date, this Warrant shall automatically expire and be forfeited in its entirety. Upon such automatic expiration, this Warrant shall be deemed void ab initio, without any further notice or action by either the Company or the Investor, and no party shall have any further rights, duties, or obligations hereunder.

 

2.2. Ownership Limitation. Notwithstanding anything to the contrary contained in this Warrant or the other Transaction Documents, if at any time Investor shall or would be issued Common Shares, but such issuance would cause Investor (together with its affiliates) to own a number of Common Shares exceeding 9.99% of the number of Common Shares outstanding on such date (the “Maximum Percentage”), Company shall not issue to Investor Common Shares which would exceed the Maximum Percentage. The foregoing Maximum Percentage is enforceable, unconditional and non-waivable and shall apply to all affiliates and assigns of Investor.

 

3. Rights of Investor. Investor shall not, by virtue of this Warrant alone, be entitled to any rights of a stockholder in Company, either at law or in equity, and the rights of Investor with respect to or arising under this Warrant are limited to those expressed in this Warrant and are not enforceable against Company except to the extent set forth herein.

 

4. Adjustments.

 

4.1. Capital Adjustments. If Company shall at any time prior to the expiration of this Warrant subdivide the Common Shares, by split-up or stock split, or otherwise, or combine its Common Shares, or issue additional Common Shares as a dividend, the number of Warrant Shares issuable upon the exercise of this Warrant shall forthwith be automatically increased proportionately in the case of a subdivision, split or stock dividend, or proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the Exercise Price and other applicable amounts, but the aggregate purchase price payable for the total number of Warrant Shares purchasable under this Warrant (as adjusted) shall remain the same. Any adjustment under this Section 4.1 shall become effective automatically at the close of business on the date the subdivision or combination becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the making of such dividend.

 

4.2. Reclassification, Reorganization and Consolidation. In case of any reclassification, capital reorganization, or change in the capital stock of Company (other than as a result of a subdivision, combination, or stock dividend provided for in Section 4.1 above), then Company shall make appropriate provision so that Investor shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares of stock and other securities and property receivable in connection with such reclassification, reorganization, or change by a holder of the same number of Common Shares as were purchasable by Investor immediately prior to such reclassification, reorganization, or change. In any such case appropriate provisions shall be made with respect to the rights and interest of Investor so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities and property deliverable upon exercise hereof, and appropriate adjustments shall be made to the purchase price per Warrant Share payable hereunder, provided the aggregate purchase price shall remain the same.

 

8
 

 

5. Certificate as to Adjustments. In each case of any adjustment or readjustment in the number or kind of shares issuable on the exercise of this Warrant, or in the Exercise Price, pursuant to the terms hereof, Company at its expense will promptly cause its Chief Financial Officer or other appropriate designee to compute such adjustment or readjustment in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based, including a statement of (a) the consideration received or receivable by Company for any additional Common Shares issued or sold or deemed to have been issued or sold, (b) the number of Common Shares outstanding or deemed to be outstanding, and (c) the Exercise Price and the number of Common Shares to be received upon exercise of this Warrant, in effect immediately prior to such adjustment or readjustment and as adjusted or readjusted as provided in this Warrant. Nothing in this Section 5 shall be deemed to limit any other provision contained herein.

 

6. Transfer to Comply with the Securities Act. Neither this Warrant nor the Warrant Shares may be sold, transferred, pledged or hypothecated without (a) an effective registration statement under the Securities Act of 1933, as amended (the “1933 Act”), relating to such security or (b) an opinion of counsel reasonably satisfactory to Company that registration is not required under the 1933 Act; provided, however, that the foregoing restrictions on transfer shall not apply to the transfer of the Warrant to an affiliate of Investor. Upon receipt of a duly executed assignment of this Warrant, Company shall register the transferee thereon as the new holder on the books and records of Company and such transferee shall be deemed a “registered holder” or “registered assign” for all purposes hereunder and shall have all the rights of Investor under this Warrant. Until this Warrant is transferred on the books of Company, Company may treat Investor as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary.

 

7. Notices. Any notice required or permitted hereunder shall be given in the manner provided in the subsection titled “Notices” in the Purchase Agreement, the terms of which are incorporated herein by reference.

 

8. Supplements and Amendments; Entire Agreement. This Warrant may be amended or supplemented only by an instrument in writing signed by the parties hereto. This Warrant, together with the Purchase Agreement, contains the full understanding of the parties hereto with respect to the subject matter hereof and thereof and there are no representations, warranties, agreements or understandings with respect to the subject matter hereof and thereof other than as expressly contained herein and therein.

 

9. Purchase Agreement; Arbitration of Disputes; Calculation Disputes. This Warrant is subject to the terms, conditions and general provisions of the Purchase Agreement, including without limitation the Arbitration Provisions (as defined in the Purchase Agreement). In addition, notwithstanding the Arbitration Provisions, in the case of a dispute as to any Calculation (as defined in the Purchase Agreement), such dispute will be resolved in the manner set forth in the Purchase Agreement.

 

10. Governing Law; Venue. This Warrant shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of Utah, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Utah or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Utah. The provisions set forth in the Purchase Agreement to determine the proper venue for any disputes are incorporated herein by this reference.

 

9
 

 

11. Remedies. The remedies at law of Investor under this Warrant in the event of any default or threatened default by Company in the performance of or compliance with any of the terms of this Warrant are not and will not be adequate and, without limiting any other remedies available to Investor in the Transaction Documents, at law or equity, to the fullest extent permitted by law, such terms may be specifically enforced by a decree for the specific performance of any agreement contained herein or by an injunction against a violation of any of the terms hereof or otherwise without the obligation to post a bond.

 

12. Liquidated Damages. Company and Investor agree that in the event Company fails to comply with any of the terms or provisions of this Warrant, Investor’s damages would be uncertain and difficult (if not impossible) to accurately estimate because of the parties’ inability to predict future interest rates, future share prices, future trading volumes and other relevant factors. Accordingly, Investor and Company agree that any fees or other charges assessed under this Warrant are not penalties but instead are intended by the parties to be, and shall be deemed, liquidated damages (under Investor’s and Company’s expectations that any such liquidated damages will tack back to the Issue Date for purposes of determining the holding period under Rule 144 under the 1933 Act, if applicable).

 

13. Counterparts. This Warrant may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. Electronic signatures shall be considered original signatures for all purposes hereof.

 

14. Severability. Whenever possible, each provision of this Warrant shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be invalid or unenforceable in any jurisdiction, such provision shall be modified to achieve the objective of the parties to the fullest extent permitted and such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Warrant or the validity or enforceability of this Warrant in any other jurisdiction.

 

15. Time is of the Essence. Time is expressly made of the essence with respect to each and every provision of this Warrant.

 

16. Descriptive Headings. Descriptive headings of the sections of this Warrant are inserted for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof.

 

[Remainder of page intentionally left blank; signature page follows]

 

10
 

 

IN WITNESS WHEREOF, Company has caused this Warrant to be duly executed as of the Issue Date.

 

  COMPANY:
     
  BirchBioMed Inc.
     
  By: /s/ Mark S. Miller
    Mark S. Miller, Chief Executive Officer

 

[Signature Page to Warrant]

 

 
 

 

ATTACHMENT 1

DEFINITIONS

 

For purposes of this Warrant, the following terms shall have the following meanings:

 

A1. “Common Shares” means common shares of Company.

 

A2. “DTC” means the Depository Trust Company or any successor thereto.

 

A3. “DWAC” means the DTC’s Deposit/Withdrawal at Custodian system.

 

A4. “Exercise Price” means the Nasdaq Valuation Price.

 

A5. “Expiration Date” means the date that is three (3) years from the Listing Date, unless earlier terminated pursuant to Section 2.1(e).

 

A6. “Initial Pre-Paid Closing Date” means the date of the issuance and sale of the Initial Pre-Paid Purchase pursuant to the Purchase Agreement.

 

A7. “Initial Pre-Paid Purchase” means the Pre-Paid Purchase #1 under the Purchase Agreement in the original principal amount of $5,425,000.00.

 

A8. “Listing Date” means the first date on which the Common Shares are listed for trading on Nasdaq.

 

A9. “Nasdaq” means the Nasdaq Stock Market.

 

A10. “Nasdaq Valuation Price” means either (a) the Valuation based Bid Price, or (b) the Compelling Evidence-based Bid Price, as submitted by Company and accepted by Nasdaq in Company’s direct listing application with Nasdaq, and calculated in accordance with Nasdaq Listing Rule IM-5405-1 or 5505-1, as applicable.

 

A11. “Trading Day” means any day Nasdaq is open for trading.

 

A12. “Transaction Documents” means the Purchase Agreement, Prepaid Purchases, this Warrant, and all other documents, certificates, instruments and agreements entered into or delivered in conjunction therewith, as the same may be amended from time to time.

 

A13. “VWAP” means the volume-weighted average price of the Common Shares on the principal market for a particular Trading Day or set of Trading Days, as the case may be.

 

 
 

 

EXHIBIT A

 

NOTICE OF EXERCISE OF WARRANT

 

The undersigned hereby irrevocably elects to exercise the right, represented by the Warrant to Purchase Shares of Common Stock dated as of November 3, 2026 (the “Warrant”), to purchase Common Shares of BirchBioMed Inc., and tenders herewith payment in accordance with Section 2 of the Warrant, as follows:

 

Date:

 

Warrant Shares: _______________________

 

Exercise Price: $_______________________

 

Purchase Price: $___________________ = (Exercise Price x Warrant Shares)

 

Please transfer the Warrant Shares electronically (via DWAC) to the following account:

 

Broker: _____________________   Address:  
DTC#: _____________________      
Account #: __________________      
Account Name: _______________    

 

  Streeterville Capital, LLC
     
  By:  
    John Fife, President